scientist using microscope

Q3 Earnings Preview for Syros Pharmaceuticals (NasdaqGS:SYRS)

in EARNINGS/INVESTING IDEAS by

Syros Pharmaceuticals, Inc. (NasdaqGS:SYRS) is scheduled to report Q3 earnings results on November 5, 2020.

The company is expected to report earnings of -$0.40/share on revenue of $2.544 million. The consensus earnings per share (EPS) of -$0.40/share is based on a poll of 6 analysts and represents a growth in eps of 14.5% over the same quarter last year, when the company reported earnings of -$0.47/share.

The revenue forecast of $2.544 million based on a poll of 8 analysts implies a year-over-year (YoY) growth in revenue of 355.9%. Last year the company reported $558 thousand in revenue for the quarter.

Expected to report EPS of -$0.40/share for Q3, 2020
Metric Expected Prior Year YoY Change
Revenue $2.54 $0.56 355.9%
EPS -$0.40 -$0.47 14.5%

Earnings Call Trends

Historically, management has exceeded analyst expectations 5 out of the last 8 tracked quarters, and missed expectations 3 quarters.

What are your expectations from Syros Pharmaceuticals, Inc. for earnings this quarter? Let us know in the comments!

Analyst Expected vs. Reported EPS
Quarter Expected Reported Surprise Result
Q2, 2020 -$0.42 -$0.38 9.5% Beat
Q1, 2020 -$0.47 -$0.39 16.3% Beat
Q4, 2019 -$0.48 -$0.46 5.0% Beat
Q3, 2019 -$0.48 -$0.47 2.1% Beat
Q2, 2019 -$0.41 -$0.47 -14.6% Missed
Q1, 2019 -$0.56 -$0.49 12.5% Beat
Q4, 2018 -$0.49 -$0.54 -9.3% Missed
Q3, 2018 -$0.45 -$0.47 -3.5% Missed

In the following table, we summarize the company’s stock price movements after earnings releases. The “Price Day Prior” column shows the closing stock price on the day before the earnings report, and the “Price Next Day” column shows the stock price at the end of the trading day after the earnings report. After the last earnings report for the period ending June 30, 2020, the stock price reacted by increasing 8.2%.

Stock Price Performance After Earnings
Report Date Price Day Prior Price Next Day Change % Result
August 6, 2020 $11.28 $12.20 8.2% Increase
May 7, 2020 $9.10 $9.70 6.6% Increase
March 5, 2020 $6.25 $6.61 5.8% Increase
November 12, 2019 $4.99 $5.24 5.0% Increase

Fundamentals And Technical Analysis

Syros Pharmaceuticals, Inc. is currently trading at $6.67/share, down −3.1% for the day. The company is trading at approximately 45.4% of its 52-week high of $14.69/share. The company’s stock price is down −45.3% since the last earnings report and down −11.4% over the previous week. The company’s 14 Day Relative Price Index (RSI) of 31.58 suggests the company is trading in technically neutral territory. The RSI is considered overbought when above 70 and oversold when below 30.


NasdaqGS:SYRS Stock Price Chart
Source: Finbox

The current share price implies a price-to-earnings (P/E) multiple of −4.13 and a forward P/E multiple of −4.47.

Syros Pharmaceuticals, Inc.’s current share price also implies a price-to-book (P/B) multiple of 4.89. The following table summarizes some other key fundamental ratios:

Data as of November 1, 2020
Metric Value
Last Reported Fiscal Period Key FY2020.Q2
Period End Date June 30, 2020
Stock Price (Current) $6.67
P/E Ratio −4.1x
P/E Ratio (Fwd) −4.5x
PEG Ratio −0.3
Total Debt / Total Capital 13.0%
Levered Free Cash Flow -$47.524 million
EV / EBITDA −3.4x

Finbox

Syros Pharmaceuticals, Inc. is a small-cap stock with a market capitalization of $305.2 million and a total enterprise value of $243.6 million. The company operates in the Healthcare sector and the Biotechnology industry.

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company’s lead product candidates are SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subset of patients with acute myeloid leukemia and myelodysplastic syndrome; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.